^
Association details:
| Biomarker: | SPP1 elevation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prognostic and Predictive Biomarkers in Metastatic Colorectal Cancer Patients Receiving Regorafenib
Published date:
08/03/2020
Excerpt:
Higher baseline levels of OPN (Pintx=0.0167), VCAM-1 (Pintx=0.0216), and PDGF-AA (Pintx=0.0435) appeared to predict for PFS benefit from regorafenib compared to placebo.
DOI:
10.1158/1535-7163.MCT-20-0249
